Incidence and Outcome of Contrast-associated Acute Kidney Injury in a Mixed Medical-surgical ICU Population: a Retrospective Study
Overview
Affiliations
Background: Contrast-enhanced radiographic examinations carry the risk of contrast-associated acute kidney injury (CA-AKI). While CA-AKI is a well-known complication outside the intensive care unit (ICU) setting, data on CA-AKI in ICU patients are scarce. Our aim was to assess the incidence and short-term outcome of CA-AKI in a mixed medical-surgical ICU population.
Methods: We conducted a single-center retrospective analysis between September 2006 and December 2008 on adult patients who underwent a contrast-enhanced computed tomography for urgent diagnostic purposes. CA-AKI was defined as either a relative increment in serum creatinine of ≥ 25% or an absolute increment in serum creatinine of ≥ 0.3 mg/dL within 48 hrs after contrast administration. ICU mortality rates of patients with and without CA-AKI were compared in univariate and multivariate analyses. The need for renal replacement therapy (RRT) was also recorded.
Results: CA-AKI occurred in 24/143 (16.8%) patients. Coexisting risk factors for kidney injury, such as sepsis, nephrotoxic drugs and hemodynamic failure were commonly observed in patients who developed CA-AKI. ICU mortality was significantly higher in patients with than in those without CA-AKI (50% vs 21%, p = 0.004). In multivariate logistic regression, CA-AKI remained associated with ICU mortality (odds ratio: 3.48, 95% confidence interval: 1.10-11.46, p = 0.04). RRT was required in 7 (29.2%) patients with CA-AKI.
Conclusions: In our cohort, CA-AKI was a frequent complication. It was associated with a poor short-term outcome and seemed to occur mainly when multiple risk factors for kidney injury were present. Administration of ICM should be considered as a potential high-risk procedure and not as a routine innocuous practice in ICU patients.
Yang C, Sung P, Chen C, Chiang J, Shao P, Wu S Stem Cell Res Ther. 2021; 12(1):526.
PMID: 34620235 PMC: 8499569. DOI: 10.1186/s13287-021-02582-5.
Chomicka I, Kwiatkowska M, Lesniak A, Malyszko J Toxins (Basel). 2021; 13(6).
PMID: 34206100 PMC: 8226462. DOI: 10.3390/toxins13060395.
Goto Y, Koyama K, Katayama S, Tonai K, Shima J, Koinuma T Crit Care. 2019; 23(1):249.
PMID: 31288864 PMC: 6615173. DOI: 10.1186/s13054-019-2517-3.
Prevention of contrast induced nephropathy; a cardiology point of view.
Hashemi M, Behjati M, Izadi S J Nephropharmacol. 2017; 4(1):23-25.
PMID: 28197470 PMC: 5297474.
Ichai C, Vinsonneau C, Souweine B, Armando F, Canet E, Clech C Ann Intensive Care. 2016; 6(1):48.
PMID: 27230984 PMC: 4882312. DOI: 10.1186/s13613-016-0145-5.